Health & Fitness
Fri, October 14, 2011Thu, October 13, 2011Wed, October 12, 2011Tue, October 11, 2011Mon, October 10, 2011Sun, October 9, 2011Sat, October 8, 2011Fri, October 7, 2011Thu, October 6, 2011Wed, October 5, 2011Tue, October 4, 2011Mon, October 3, 2011Sun, October 2, 2011Sat, October 1, 2011Fri, September 30, 2011Thu, September 29, 2011Wed, September 28, 2011Tue, September 27, 2011Mon, September 26, 2011Sat, September 24, 2011Fri, September 23, 2011Thu, September 22, 2011Wed, September 21, 2011Bronstein, Gewirtz & Grossman, LLC Investigates DaVita, Inc.
Published in Health and Fitness on Tuesday, October 4th 2011 at 18:20 GMT by Market Wire
NEW YORK--([ BUSINESS WIRE ])--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DaVita, Inc. (aDaVitaa or the aCompanya) (NYSE: DVA), concerning whether the company and certain of its officers and directors have violated federal securities laws.
DaVita disclosed in August a grand jury criminal probe by the U.S. Attorney in Denver. The Company said the Colorado investigation appears to overlap with two other ongoing federal investigations into its business. DaVita is charged with overbilling the Medicare system and overusing the drug Epogen, used to boost red blood cells for those with kidney disease. The allegations against DaVita have been publicized for some time, but Citigroup analyst Gary Taylor notes that recent rulings could start to pose significant legal risks. Under the False Claims Act a" used in the past against defense contractors that have overbilled the Pentagona"any damages the company is ordered to pay could be automatically tripled. The Denver Post reports that the grand jury is also looking into allegations that the Company entered into improper relationships with pharmaceutical companies and physicians. The stock has traded between $59.61 and $89.76 in the last year and since DaVita reported its second quarter results on August 3, 2011, the stock is down almost 20 percent.
If you are aware of any facts relating to this investigation, or purchased shares of DaVita, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [ eitan@bgandg.com ]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firma™s expertise includes general corporate work, private securities offerings, and securities arbitration.
